Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MyStart Health vs Velvet Rx

MyStart Health
Graded #328

Higher grade

vs+3.2
Velvet Rx
Graded #421

Lower grade

The verdict

MyStart Health takes it — 61.3/100 to 58.1/100.

MyStart Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MyStart Health offers all-inclusive compounded semaglutide and tirzepatide at $299/month with a price-lock guarantee, same-day physician consultations, and 24/7 care team access.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMyStart Health +6
48
42
Dose & formulationMyStart Health +8
83
75
Clinical oversightVelvet Rx +12
55
67
Labs & monitoringMyStart Health +13
66
53
FulfillmentMyStart Health +21
78
57
Contract termsVelvet Rx +24
31
55
MyStart Health · left barVelvet Rx · right bar

The numbers

MetricMyStart HealthVelvet Rx
WeighScore61.3/10058.1/100
GradeCC
Scorecard rank#328#421
Semaglutide$299/mo (all doses, compounded)$299/mo (compounded)
Tirzepatide$299/mo (all doses, compounded)$359/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
MyStart Health

Graded #328 · C

FDAWarning letter issued to Matthew Stern, CEO MyStart Health LLC. in September 2025. See the FDA warning-letter database.

Strengths

  • Price Lock Guarantee — your $299 base rate doesn't rise as your dose escalates
  • Fast onboarding: roughly 5-minute intake, 24-hour prescription turnaround, 2–4 day shipping
  • 24/7 care team access with unlimited clinician messaging included
  • LegitScript certified
  • Clear Section 503A compounding disclosure on every landing page

Where it loses points

  • Not BBB accredited — C+ rating with 10 complaints, mostly shipping delays and support access
  • Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro
  • Markets oral tirzepatide, but no FDA-approved oral tirzepatide exists
  • Very new company (incorporated May 2024) with a limited track record
  • FDA issued Matthew Stern, CEO MyStart Health LLC. a warning letter in September 2025; the letter is public in FDA's warning-letter database
Velvet Rx

Graded #421 · C

Strengths

  • Public pricing across 3 SKUs (semaglutide $299, tirzepatide $359, oral GLP-1 $349) — uncommon in compounded telehealth
  • First-month promo pricing shown upfront ($139 sema / $199 tirz / $189 oral)
  • Single monthly price includes consult, prescription, 4 weeks of medication, and free 1–2 day shipping
  • FSA/HSA eligible
  • Three options under one roof: injectable sema, injectable tirz, and an oral GLP-1

Where it loses points

  • Oral GLP-1 SKU doesn't name the specific drug — a real gap given Rybelsus, Foundayo, and compounded oral semaglutide differ clinically
  • No LegitScript or NABP.pharmacy seal displayed
  • No legal entity name disclosed
  • No physical address disclosed
  • Compounding pharmacy partner not named

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 544 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard